- AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . .
Anonymous board for AstraZeneca
- AstraZeneca | Cafepharma
AstraZeneca’s Imfinzi can now be used to treat patients with gastric and gastroesophageal junction cancers as part of a chemotherapy combination, adding another indication for the blockbuster PD-L1 inhibitor
- Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical device sales, lab diagnostics sales
- Cafepharma News
Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends
- AstraZenecas latest amyloidosis pact with Neurimmune could reach $780M . . .
Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset The latest licensing deal involves NI009, a preclinical monoclonal antibody that targets lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis In return for the exclusive rights, AstraZeneca’s Alexion
- Pharma Biotech Companies | Cafepharma Message Boards | Pharma Sales . . .
Anonymous discussion boards for pharmaceutical and biotech companies
- Pfizer | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous board for Pfizer
- Imfinzi | Cafepharma
AstraZeneca’s Imfinzi can now be used to treat patients with gastric and gastroesophageal junction cancers as part of a chemotherapy combination, adding another indication for the blockbuster PD-L1 inhibitor
|